Brief: Wuxi Biologics FY Revenue RMB21,790 Million
11/02/2026 01:23
Feb 11 (Reuters) - WuXi Biologics (Cayman) 2269.HK: FY REVENUE RMB 21,790 MILLION FY PROFIT EXPECTED TO INCREASE TO RMB5,733 MILLION FY ADJUSTED NON-IFRS NET PROFIT EXPECTED TO INCREASE TO RMB6,586 MILLION Further company coverage: 2269.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on WuXi Biologics (Cayman)
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
CanSino leads HK-listed vaccine makers lower as BioNTech halts mRNA trial
WuXi Biologics H1 net profit up on margin expansion
Brief: WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln